Skip to main content
MYRIAD GENETICS INC logo

MYRIAD GENETICS INC — Investor Relations & Filings

Ticker · MYGN ISIN · US62855J1043 LEI · 52990044IHUOUMETT163 US Human health and social work activities
Open in API
Filings indexed 1,311 across all filing types
Latest filing 2026-06-04 Declaration of Voting R…
Country US United States of America
Listing US MYGN

About MYRIAD GENETICS INC

https://myriad.com/

Myriad Genetics is a genetic testing and precision medicine company that develops and commercializes molecular diagnostic tests. The company's tests provide personalized and actionable insights by analyzing an individual's genetic and genomic information. These insights are used to assess the risk of developing hereditary diseases, guide treatment strategies, and inform preventative healthcare decisions. Myriad's portfolio addresses several clinical areas, including oncology, women's health, and mental health. Key offerings include the MyRisk™ test for hereditary cancer risk, Prolaris® for prostate cancer aggressiveness, EndoPredict® for breast cancer recurrence, the Foresight® and Prequel® prenatal screens, and the GeneSight® test to guide mental health medication selection. The company aims to empower patients and healthcare providers with critical information to improve health outcomes.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a Form 8-K current report filed under the Securities Exchange Act, containing the results of proposals voted on at the 2026 Annual Meeting (Item 5.07) with detailed tallies for each director election and plan amendment. This is exactly a Declaration of Voting Results & Voting Rights Announcement, matching Code DVA.
2026-06-04 English
S-8
Regulatory Filings Classification · 85% confidence The document is a Form S-8 Registration Statement filed with the SEC to register shares under an employee stock purchase plan. It is a compliance/regulatory filing rather than an earnings release, proxy, management discussion, or capital markets update. None of the specific categories directly cover Form S-8, so it falls into the general “Regulatory Filings” (RNS) fallback category.
2026-06-04 English
S-8
Share Issue/Capital Change Classification · 85% confidence The document is a Form S-8 Registration Statement filed with the SEC, which registers shares under an equity incentive plan for employees, directors, and consultants. This form facilitates the issuance of new shares under the company’s capital structure. It is not a proxy, earnings release, annual report, or managerial announcement, but specifically relates to a share issuance registration. According to the filing classification definitions, this falls under “Share Issue/Capital Change” (SHA).
2026-06-04 English
10-Q - MYRIAD GENETICS INC (0000899923) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-06 English
8-K
Report Publication Announcement Classification · 75% confidence The document is a short Form 8-K (4463 characters) that contains no substantive financial data itself but announces that an earnings release is attached as Exhibit 99.1. Under the “menu vs. meal” rule, such brief notices stating a report is attached are classified as Report Publication Announcements (RPA), not as the actual earnings release (ER).
2026-05-05 English
ARS - MYRIAD GENETICS INC (0000899923) (Filer)
Annual Report
2026-04-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.